A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1965-1972

  File Jr , Thomas M ^a,g   Segreti, John ^b   Dunbar, Lala ^c   Player, Richard ^d   Kohler, Richard ^e   Williams, R Rex ^f   Kojak, Clare ^f   Rubin, Arkady ^f  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Sorra Research Center   (United States)

^e WISHARD MEMORIAL HOSPITAL   (United States)

^f R W JOHNSON PHARMACEUTICAL RES I   (United States)

^g SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CEFUROXIME AXETIL; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MIXTURE; DRUG SAFETY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0343852343     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1965     Document Type: Article

References (38)

1. Abbate, G. F., I. Alagia, E. Giaquinto, V. Leonessa, L. Savioli, P. Altucci, M. Caputi, C. Guarino, E. Micillo, and E. Catena. 1986. Treatment of lower respiratory tract infections with ceftriaxone and cefotaxime. Respiration 49:222-230.
2. Bartlett, J. G., and L. M. Mundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333:1618-1624.
3. Bittner, M. J., M. D. Pugsley, E. A. Horowitz, D. G. Strike, C. C. Sanders, and L. D. Preheim. 1986. Randomized comparison of ceftriaxone and cefamandole therapy in lower respiratory tract infections in an elderly population. J. Antimicrob. Chemother. 18:621-627.
4. Bonnet, J. P., D. Ginsberg, and T. M. Nolen. 1992. Cefprozil vs. cefuroxime axetil in mild to moderate lower respiratory tract infections; analysis of patients with bronchitis. Infect. Med. 9(Suppl. E):48-56.
5. British Thoracic Society. 1993. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br. J. Hosp. Med. 49:346-350.
6. Chien, S.-c., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. Pharmacokinetic profile of levofloxacin following once-daily 500 milligram oral or intravenous doses. Antimicrob. Agents Chemother., in press.
7. Cooper, T. J., E. Ladusans, P. E. O. Williams, V. Polychronopoulos, H. Gaya, and R. M. Rudd. 1985. A comparison of oral cefuroxime axetil and oral amoxycillin in lower respiratory tract infections. J. Antimicrob. Chemother. 16:373-378.
8. DeAbate, C. A. 1995. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir. Care 42:206-213.
9. Fang, G. D., M. Fine, J. Orloff, D. Arisumi, V. L. Yu, W. Kapoor, J. T. Graystou, S. P. Wang, R. Kohler, R. R. Muder, et al. 1990. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 69:307-316.
10. Fass, R. J. 1993. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J. Antimicrob. Chemother. 32(Suppl. A):17-27.
11. Fogarty, C. M. 1995. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of community-acquired pneumonia in adults. Presented at the International Congress of Chemotherapy, Montreal, Quebec, Canada, 17 to 19 July 1995.
12. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
13. Fujimoto, T., and S. Mitsuhashi. 1990. In vitro antibacterial activity of DR-3355, the S-(-) isomer of ofloxacin. Chemotherapy 36:268-276.
14. Grasela, T. H., J. A. Paladino, J. J. Schentag, D. Huepenbecker, J. Rybacki, J. B. Purcell, and J. B. Fiedler. 1991. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP Ann. Pharmacother. 25:857-862.
15. Grassi, C., and P. Mangianotti. 1987. International experiences with ceftriaxone in the treatment of lower respiratory tract infections. Chemotherapia 6:364-373.
16. Grayston, J. T., V. K. Diwan, M. Cooney, and S.-P. Wang. 1989. Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch. Intern. Med. 149:169-173.
17. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
18. Hardy, D. J., D. M. Hensey, J. M. Beyer, C. Vojtko, E. J. McDonald, and P. B. Fernandes. 1988. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32:1710-1719.
19. Hauck, W., and S. Anderson. 1986. A comparison of large sample confidence interval methods for the difference of two binomial probabilities. Am. Stat. 40:318-322.
20. Kauppinen, M. T., P. Saikku, P. Kujala, E. Herva, and H. Syrjala. 1996. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 51:185-189.
21. Kleemola, S. R., J. E. Karjalainen, and R. K. Raty. 1990. Rapid diagnosis of Mycoplasma pneumoniae infection: clinical evaluation of a commercial probe test. J. Infect. Dis. 162:70-75.
22. Klugman, K. P., and T. Capper. 1995. Levofloxacin in vitro activity and synergistic activity in combination with other antibacterials against antibiotic-resistant S. pneumoniae, and selection of resistant mutants, abstr. E9, p. 87. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Kuo, C.-C., L. A. Jackson, L. A. Campbell, and J. T. Grayston. 1995. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:451-461.
24. Lee, B. L., A. M. Padula, R. C. Kimbrough, S. R. Jones, R. E. Chaisson, J. Mills, and M. A. Sande. 1991. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med. 325:520-521.
25. Mandell, L. A., M. G. Bergeron, A. R. Ronald, C. Vega, G. Harding, R. Saginur, R. Feld, R. Duperval, S. J. Landis, L. J. Miedzinski, et al. 1989. Once-daily ceftriaxone compared with daily multiple dose therapy with cefotaxime for serious bacterial infections: a randomized double-blind study. J. Infect. Dis. 160:443-447.
26. Markus, A., D. Isert, N. Kiesel, and G. Seibert. 1995. Killing activity of levofloxacin (LEV) and ciprofloxacin (CIP) against Streptococcus pneumoniae in vitro and in vivo, abstr. E30, p. 90. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
27. Marrie, T. J., J. T. Grayston, S.-P. Wang, and C.-C. Kuo. 1987. Pneumonia associated with the TWAR strain of Chlamydia. Ann. Intern. Med. 106:507-511.
28. Massachusetts Medical Society. 1995. Pneumonia and influenza death rates - United States, 1979-1994. Morbid. Mortal. Weekly Rep. 44:535-537.
29. National Committee for Clinical Laboratory Standards. 1988. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards. Villanova, Pa.
30. National Committee for Clinical Laboratory Standards. 1983. Performance standards for antimicrobial disk susceptibility tests. M2-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
31. Neu, H. C., and K. P. Fu. 1978. Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity. Antimicrob. Agents Chcmothcr. 13:657-664.
32. Paladino, J. A., H. E. Sperry, J. M. Backes, J. A. Gelber, D. J. Serrianne, T. J. Cumbo, and J. J. Schentag. 1991. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am. J. Med. 91:462-470.
33. Plouffe, J. F., M. T. Herbert, T. M. File, Jr., I. Baird, J. N. Parsons, J. B. Kahn, K. T. Rielly-Gauvin, and The Pneumonia Study Group. 1996. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob. Agents Chemother. 40:1175-1179.
34. Potgieter, P. D., D. M. Linton, A. A. Forder, and H. Plumb. 1986. Ceftriaxone therapy in adults with severe lower respiratory tract infections. S. Afr. Med. J. 69:495-497.
35. Richards, D. M., R. C. Heel, R. N. Brodgen, T. M. Speight, and G. S. Avery. 1984. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27:469-527.
36. Schleupner, C. J., W. C. Anthony, J. Tan, T. M. File, P. Lifland, W. Craig, and B. Vogelman. 1988. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch. Intern. Med. 148:343-348.
37. Sydnor, T. A., W. M. Scheld, and J. M. Gwaltney. 1995. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of acute bacterial sinusitis in adults. Presented at the International Congress of Chemotherapy, Montreal, Quebec, Canada, 17 to 19 July 1995.
38. Une, T., T. Fujimoto, K. Sato, and Y. Osada. 1988. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob. Agents Chemother. 32: 1336-1340.